Keyword: AstraZeneca

Less than two years after jumping ship from the FDA to AstraZeneca, Badrul Chowdhury, M.D., Ph.D., is leaving the Big Pharma.

Combining AZ's MCL1 inhibitor AZD5991 with existing MEK or BRAF inhibitors could kill melanoma cells more effectively, scientists found.

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.

AstraZeneca wants its growing Chinese team to take global leadership on some projects for the first time.

Radius says it will double down on osteoporosis and endocrine diseases as looks to offload its cancer work.

The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.

After getting off a $75 million IPO last year, AstraZeneca’s antibiotics spinout Entasis has hired a former Shire executive to lead its R&D programs.

The phase 3 program was one of five projects removed from AstraZeneca’s pipeline in conjunction with its second-quarter results.

AstraZeneca landed the PDUFA date for [fam-] trastuzumab deruxtecan after the FDA accepted its approval submission for priority review.

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.